However, multiple in vitro and phase I and II studies have reported that GP2 is as effective as E75 in terms of inducing an HER2-specific immune response [100,121], making GP2 a promising antigen for an HER2-positive cancer vaccine application. The gene discussed is GP2; the disease is cancer.